Rocket Pharma counsel sells 3,493 shares for taxes

ROCKET PHARMACEUTICALS, INC. executive Martin Wilson, General Counsel, reported a sale of 3,493 shares of common stock on 2026-08-13 at $3.381 per share.

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. executive Martin Wilson, General Counsel, reported a sale of 3,493 shares of common stock on 2026-08-13 at $3.381 per share. The sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units, and Wilson now holds 674,484 shares directly, including RSUs that convert to common stock on a one-for-one basis.

Insider Trade Summary

Net Seller: 3,493 shares

Net Sell 1 txn

Insider Wilson Martin

Role General Counsel

Sold 3,493 shs ($12K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	3,493	$3.381	$12K

Holdings After Transaction: Common Stock — 674,484 shares (Direct)

Footnotes (2)

1. F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
2. F2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Key Figures

Shares Sold: 3,493 shares Sale Price: $3.381 per share Shares Owned After: 674,484 shares

3 metrics

Shares Sold 3,493 shares Common stock sale reported on 2026-08-13

Sale Price $3.381 per share Price for the 3,493 common shares sold

Shares Owned After 674,484 shares Total direct holdings after the reported sale, including RSUs

Key Terms

Restricted Stock Units ("RSUs"), tax withholding obligations, beneficially owns

3 terms

Restricted Stock Units ("RSUs") financial

"Holdings include Restricted Stock Units ("RSUs") that convert to common stock"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligations financial

"sold by the Reporting Person in order to pay tax withholding obligations"

beneficially owns financial

"Holdings include Restricted Stock Units ("RSUs") that convert to common stock"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RCKT General Counsel Martin Wilson report?

Martin Wilson reported a sale of 3,493 RCKT common shares on 2026-08-13 at $3.381 per share. The company states the shares were sold to satisfy tax withholding obligations related to vesting Restricted Stock Units.

How many RCKT shares did Martin Wilson sell and at what price?

Martin Wilson sold 3,493 shares of ROCKET PHARMACEUTICALS (RCKT) common stock at $3.381 per share. This transaction was reported as a sale in connection with tax withholding on vesting RSUs, not a discretionary liquidation of his entire position.

Why did RCKT’s General Counsel sell 3,493 shares of stock?

The filing states the 3,493 RCKT shares were sold to pay tax withholding obligations tied to the vesting of Restricted Stock Units. This indicates the transaction was related to equity compensation taxes rather than a broad reduction of ownership.

What is Martin Wilson’s RCKT share ownership after this reported sale?

Following the transaction, Martin Wilson beneficially owns 674,484 RCKT shares directly. The filing notes these holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis when they vest.

Does the Form 4 indicate any derivative or option exercises for RCKT by Martin Wilson?

No derivative or option exercises are reported; the Form 4 shows one non-derivative sale of 3,493 RCKT common shares. A footnote clarifies that the sale was connected to tax withholding on vesting RSUs, not an option exercise event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 05:50 PM EDT Accepted by SEC EDGAR 08/17/2026 - 05:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson Martin

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NEW JERSEY 08512

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	08/13/2026		S(2)		3,493	D	$3.381	674,484(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

	/s/ Martin Louis Wilson	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)